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Screening for Primary Open-Angle Glaucoma 
in the Primary Care Setting: An Update for 
the US Preventive Services Task Force
ABSTRACT
PURPOSE Primary open-angle glaucoma (POAG) is a leading cause of blindness 
and vision-related disability. This review examines the effectiveness of screening 
for and treatment of early POAG in asymptomatic persons. 
METHODS We identifi ed studies of glaucoma screening and treatment from MEDLINE,
the Cochrane Library, and glaucoma experts. Two reviewers abstracted relevant 
studies and graded articles according to US Preventive Services Task Force criteria.
RESULTS No randomized, controlled trials of population screening for POAG have 
been reported. Two randomized controlled trials compared the effi cacy of treat-
ment to lower intraocular pressure with no treatment for persons who have early 
primary open-angle glaucoma. In a Swedish trial, treatment reduced progression 
at 5 years from 62% without treatment to 45% with treatment (absolute risk 
reduction [ARR] 17%, number needed to treat 5.8, P = .007). In a US trial of 
patients with early POAG and normal intraocular pressure, progression at 5 years 
was observed in 39% of those without treatment and 33% of those with treatment 
(P = .21). The benefi t of delaying progression of visual fi eld loss on vision-related 
function in patients with early POAG is unclear. The principal harm of treatment is 
loss of visual acuity resulting from an increased risk of cataract formation. 
CONCLUSIONS Treatment to lower intraocular pressure may delay progression of 
visual fi eld defi cits in some asymptomatic individuals with early POAG. Further 
studies of population screening are needed to show that early recognition and 
treatment of glaucoma in asymptomatic patients are effective in improving vision-
specifi c functional outcomes and health-related quality of life. 
Ann Fam Med 2005;3:167-170. DOI: 10.1370/afm.293.
INTRODUCTION
Glaucoma is an optic nerve neuropathy that leads to progressive visual fi eld loss. Primary open-angle glaucoma (POAG), the most common type, affects an estimated 2.5 million persons in the 
United States, 130,000 of whom will be blind as a result.1 In most patients 
with POAG, however, loss of vision occurs so slowly that the average 
patient with POAG diagnosed at age 60 years will probably not become 
legally blind in either eye within his or her lifetime.2
A defi nitive POAG diagnosis is based on characteristic degenerative 
changes in the optic disc and progressive loss of visual fi eld sensitivity. 
Although most persons with POAG have intraocular pressures of greater 
than 21 mm Hg (the upper limit of normal), 25% to 50% have normal 
intraocular pressure measurements, a condition known as normal-tension 
glaucoma.3 Other risk factors include advanced age and family history of 
glaucoma.4 African descent is also an important risk factor. POAG preva-
lence in blacks is 4 times greater than in whites5 and is the leading cause of 
blindness in African Americans.
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In 1996, the United States Preventive Services Task 
Force (USPSTF) found insuffi cient evidence to recom-
mend for or against routine glaucoma screening in pri-
mary care practice.6 The USPSTF noted that although 
glaucoma treatment with medications or surgery to 
lower intraocular pressure had been the standard of 
care for many years, defi nitive evidence supporting 
the benefi t of treating persons with early glaucoma 
and minimal visual impairment was not available. To 
support an updated USPSTF recommendation, we 
critically reviewed the literature for new evidence on 
the effectiveness of screening and treatment for early 
POAG. This article briefl y summarizes the fi ndings of 
the full review, which is available online at http://www.
preventiveservices.ahrq.gov/.
METHODS
We searched MEDLINE, the Cochrane Database of 
Systematic Reviews, and the Cochrane Controlled 
Trials Register from 1994 to May 2004 to identify ran-
domized clinical trials of screening for and treatment of 
primary POAG. We identifi ed additional studies from 
citations in relevant articles and experts in glaucoma 
screening and treatment. Two reviewers abstracted rel-
evant information and graded articles according to US 
Preventive Services Task Force criteria.7 
RESULTS
Screening for POAG
We found no randomized, controlled trials examining 
the effectiveness of screening and treating asymptom-
atic individuals for POAG in reducing or delaying pro-
gression of vision-related functional impairment. We 
also found no prospective studies examining the accu-
racy and reliability of screening for early POAG among 
asymptomatic patients in the primary care setting.
Although increased intraocular pressure is a risk 
factor for glaucoma, the effectiveness of intraocular 
pressure measurement as a population-screening tool 
for POAG appears to be limited. Many persons with 
POAG have normal intraocular pressure. Intraocular 
pressure measurements above the usual cutoff point 
(greater than 21 mg Hg) have an estimated sensitivity 
of 47% and specifi city of 92% for diagnosing POAG, 
and intraocular pressure measurement does not appear 
to perform better in high-risk groups defi ned by age, 
race, sex, or family history.8
Degenerative changes in the optic disc are char-
acteristic of POAG. A dilated eye examination with 
direct ophthalmoscopy by an ophthalmologist has a 
reported sensitivity of 59% and a specifi city of 73% for 
detecting and classifying optic disc changes associated 
with glaucoma.9 No data are available on the accuracy 
and reliability of direct ophthalmoscopy by primary 
care physicians for detecting degenerative optic disc 
changes associated with early POAG.
POAG also leads to characteristic patterns of visual 
fi eld loss that are important to a defi nitive diagnosis.2 
Perimetry assesses visual fi eld defi cits by mapping a 
patient’s response to visual stimuli in various locations 
within the visual fi eld. The reported sensitivity and 
specifi city of perimetry varies based on the method 
used and the cutoff point for defi ning visual fi eld 
defects, as well the test used as the reference standard.10 
The American Academy of Ophthalmology does not 
recommend visual fi eld screening by perimetry as part 
of an eye specialist’s medical examination.11
Prevention and Treatment of Early POAG
We found one good-quality randomized trial in patients 
with ocular hypertension (intraocular pressure greater 
than 21 mm Hg) examining the effi cacy of treatment to 
delay onset of POAG with topical medications to lower 
intraocular pressure compared with no treatment. At 5 
years, 4.4% of treated patients and 9.5% of untreated 
patients developed POAG (hazard ratio, 0.40; 95% CI, 
0.27-0.59; number need to treat [NNT] 19.6).12 Because 
most patients with ocular hypertension do not develop 
POAG, however, whether ocular hypertension should be 
treated before the onset of POAG is controversial.13,14
Several recent randomized trials have examined the 
effi cacy of different treatment regimens for POAG.15-18 
Only 2 trials compared treated patients with an 
untreated control group.19,20
The Early Manifest Glaucoma Trial (EMGT)19 was 
a good-quality Swedish trial comparing the effi cacy of 
treatment with argon laser trabeculoplasty and topical 
medications vs no treatment for 255 white participants 
with newly diagnosed, early POAG. After a median 
follow-up period of 6 years, a trial endpoint of POAG 
progression based on new visual fi eld loss, optic disc 
deterioration, or both, was observed in 45% of treated 
patients vs 62% of the control group (absolute risk 
reduction [ARR] 17%; NNT 5.9; P = .007) The median 
time to progression was 66 months in treated patients 
compared with 48 months in the control group.
The EMGT study included patients with early 
POAG who had either normal or elevated intraocular 
pressure. A second controlled trial, the Collaborative 
Normal-Tension Glaucoma Study (CNTGS),21 included 
only patients with early POAG and normal intraocular 
pressure. CNTGS was a fair-quality trial comparing 
surgery and topical medication with no treatment in 1 
eye each of 145 persons with normal tension glaucoma. 
At 5 years, an endpoint based on worsening of existing 
visual fi eld defects or appearance of new visual fi eld 
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defect was observed in 22 of 66 (33%) treated eyes and 
31 of 79 (39%) untreated eyes (P = .21). 
In the CNTGS study, 23 of 66 treated eyes (35%) 
developed visual acuity loss as a result of cataracts, com-
pared with 11 of 79 eyes in the control group (14%) (P 
= .0011). In a secondary analysis, censoring eyes from 
further observation at the time cataracts were diagnosed 
resulted in an apparent reduction in glaucoma progres-
sion for treated eyes compared with control eyes (P = 
.008). This analysis, however, did not account for possible 
glaucoma progression that may occur after cataracts devel-
oped. Because most cataracts occurred in treated patients, 
censoring may have introduced a bias favoring treatment.
Benefi ts of Treatment for Early POAG
Two questions arise when interpreting the benefi ts of 
treatment for early POAG based on clinical trial out-
comes. The fi rst question is what progression means. 
Presently, there is no standard method for measuring 
visual fi eld loss in POAG. To reduce potential harms 
for untreated patients, both EMGT and CNTGS used 
sensitive measures of visual fi eld loss as progression end-
points. A study comparing progression endpoints used in 
EMGT and 2 other trials evaluating different treatment 
regimens found that the 3 endpoints were in agreement 
when classifying progression for only 23% of patients.22 
The second question is how progression affects 
patients’ self-reported visual function or health-related 
quality of life. In a study of glaucoma patients with 
moderate-to-marked visual fi eld loss, greater visual fi eld 
loss was associated with signifi cant decreases in self-
reported visual function and general health measures.23 
The absolute differences in scores between glaucoma 
and reference patients with cataracts were small, how-
ever, and the clinical importance of these differences 
was not clear. A second study found moderate correla-
tions between decreased self-reported visual function 
and both visual fi eld loss and loss of visual acuity.24 
Adjustment for loss of visual acuity, however, reduced 
the correlation between visual fi eld loss and decreased 
visual function. Other studies reportedly underway may 
clarify the relation between visual fi eld loss in early 
POAG and vision-related function and quality of life.
Potential Harms of Treatment for Early POAG
The harms of treating early asymptomatic POAG are 
important when determining the net benefi t of treat-
ment. Based on the 6-year results of the EMGT trial, 
for example, only 1 in 6 patients would be expected 
to benefi t from treatment (ARR 0.21, NNT 5.9). The 
other 5 patients may be exposed to potential harms of 
treatment without defi nite benefi t.19
The chief harm of treatment is increased risk of 
cataract formation, particularly with surgery, which may 
lead to decreased visual acuity. In the EMGT study, 
treated patients received medication and/or underwent 
laser treatment. In the treatment group, 6 of 125 (4.8%) 
of patients had cataract surgery compared with 2 of 122 
(1.6%) in the control group (number needed to harm 
[NNH] 31; P = .148). Visual acuity decreased at similar 
rates with time in both treated patients and the control 
group. In the CNTGS study, patients in the treatment 
group received either medication, laser treatment, or 
surgery to achieve a predetermined reduction of intra-
ocular pressure.21 In the treatment group, 23 of 61 
patients (38%) developed cataracts compared with 11 of 
79 (14%) in the control group (NNH 4.8; P = .0011). 
In the treatment group, 16 of 33 (48%) surgically 
treated patients developed cataracts compared with 7 
of 23 (30%) patients treated with medication and laser 
therapy (P = .059). No information was reported on the 
number of patients who underwent cataract surgery and 
the impact on visual acuity between treatment and con-
trol group patients.
In another trial comparing medical with surgical 
treatment in patients who had early POAG, surgery 
was associated with a signifi cantly greater loss in visual 
acuity during 3.5 years of follow-up.18 Ocular symp-
toms, such as dryness, excessive tearing, and itching 
occur at similar rates in medically and surgically treated 
patients. Systemic medication side effects (eg, cardio-
vascular or mental) are uncommon.4
DISCUSSION
No studies examine whether population-based screening 
of asymptomatic persons for early open-angle glaucoma 
is effective in improving vision-specifi c function and qual-
ity of life. There is good evidence that treatment to lower 
intraocular pressure may delay the onset and progression 
of visual fi eld defi cits in some asymptomatic patients 
with ocular hypertension who do not have POAG (NNT 
19.6) and in patients with early primary open-angle 
glaucoma (NNT 5.9). Treatment does not appear to 
benefi t patients with POAG who have normal intraocular 
pressure. There are presently no studies that make it pos-
sible to interpret the benefi t of treatment as a means of 
preserving vision-specifi c function. The potential benefi ts 
of treatment must be weighed against potential harms, 
particularly the increased risk for cataract formation.
Population-based glaucoma screening trials using 
vision-specifi c function and quality-of-life outcomes 
would be helpful to determine whether early recogni-
tion and treatment of open-angle glaucoma is benefi -
cial. Because blacks are at greater risk for developing 
POAG, population-based trials will need to include a 
number of black participants suffi cient to detect poten-
tial screening benefi ts.
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To read or post commentaries in response to this article, see it 
online at http://www.annfammed.org/cgi/content/full/3/2/167. 
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